The most widely research are immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen-4 (CTLA-4), which have shown significant benefits in the treatment of advanced CRC [3]. The gene discussed is CD274; the disease is colorectal carcinoma.